<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of hypercalcemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of hypercalcemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of hypercalcemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth Shane, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford J Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercalcemia can be produced by a variety of disorders, but primary hyperparathyroidism and malignancy account for most cases (see
         <a class="medical medical_review" href="/z/d/html/839.html" rel="external">
          "Etiology of hypercalcemia"
         </a>
         ). It may be associated with a spectrum of clinical manifestations  (
         <a class="graphic graphic_table graphicRef54647" href="/z/d/graphic/54647.html" rel="external">
          table 1
         </a>
         ), ranging from few (if any) symptoms if the hypercalcemia is mild and/or chronic to obtundation and coma if it is severe and/or acute [
         <a href="#rid1">
          1,2
         </a>
         ].The symptoms and signs associated with hypercalcemia are typically independent of the etiology.
        </p>
        <p>
         This topic will review the major clinical manifestations directly associated with hypercalcemia. The clinical manifestations more directly associated with hyperparathyroidism and the diagnostic approach to and treatment of hypercalcemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">
          "Primary hyperparathyroidism: Clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/836.html" rel="external">
          "Diagnostic approach to hypercalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/850.html" rel="external">
          "Treatment of hypercalcemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7698134">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercalcemia can affect a variety of organ systems  (
         <a class="graphic graphic_table graphicRef54647" href="/z/d/graphic/54647.html" rel="external">
          table 1
         </a>
         ). The symptoms of hypercalcemia depend upon both the degree of hypercalcemia and the rate of onset of the elevation in the serum calcium concentration. In addition, there is individual variation in the manifestation of symptoms.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild hypercalcemia
         </strong>
         – Patients with mild hypercalcemia (calcium above the upper limit of normal but &lt;12 mg/dL [3 mmol/L]) may be asymptomatic, or they may report nonspecific symptoms, such as constipation, fatigue, and depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate hypercalcemia
         </strong>
         – A moderately elevated serum calcium of 12 to 14 mg/dL (3 to 3.5 mmol/L) may be well tolerated chronically, while an acute rise to these concentrations may cause marked symptoms, including polyuria, polydipsia, dehydration, anorexia, nausea, muscle weakness, and changes in sensorium  (
         <a class="graphic graphic_table graphicRef54647" href="/z/d/graphic/54647.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe hypercalcemia
         </strong>
         – In patients with severe hypercalcemia (calcium &gt;14 mg/dL [3.5 mmol/L]), there is often progression of the symptoms noted in patients with acute, moderate hypercalcemia [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          NEUROPSYCHIATRIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of mild neuropsychiatric disturbances have been associated with hypercalcemia, mostly in patients with primary hyperparathyroidism. The most common symptoms have been anxiety, depression, and cognitive dysfunction. Improvement in some or all of these symptoms has been described after correction of the hyperparathyroidism. (See
         <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">
          "Primary hyperparathyroidism: Management", section on 'Nonclassic end organ effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">
          "Primary hyperparathyroidism: Clinical manifestations", section on 'Symptomatic primary hyperparathyroidism'
         </a>
         .)
        </p>
        <p>
         More severe symptoms, including lethargy, confusion, stupor, and coma may occur in patients with moderate (calcium 12 to 14 mg/dL [3 to 3.5 mmol/L)] or severe hypercalcemia (calcium &gt;14 mg/dL [3.5 mmol/L]) from any cause [
         <a href="#rid1">
          1
         </a>
         ]. These symptoms are more likely to occur in older adults and in those with rapidly rising calcium concentrations [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GASTROINTESTINAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal symptoms, such as constipation, anorexia, and nausea, occur commonly. Constipation may be related to decreased smooth muscle tone and/or abnormal autonomic function. Pancreatitis and peptic ulcer disease occur less frequently than other gastrointestinal symptoms [
         <a href="#rid5">
          5-9
         </a>
         ]. Proposed mechanisms for the development of pancreatitis include deposition of calcium in the pancreatic duct and calcium activation of trypsinogen within the pancreatic parenchyma [
         <a href="#rid9">
          9-11
         </a>
         ]. In rats, acute hypercalcemia causes a dose-dependent increase in serum amylase and morphologic characteristics of acute pancreatitis [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Peptic ulcer disease has been described in patients with hypercalcemia due to primary hyperparathyroidism [
         <a href="#rid5">
          5
         </a>
         ] and may be caused by calcium-induced increases in gastrin secretion. In patients with multiple endocrine neoplasia type 1 (MEN1) with coexisting Zollinger-Ellison syndrome and hyperparathyroidism, parathyroidectomy alone has led to a significant reduction in serum gastrin concentrations and acid secretion [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          KIDNEY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important kidney manifestations are polyuria (resulting from decreased concentrating ability in the distal tubule), nephrolithiasis, and acute and chronic kidney insufficiency.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Arginine vasopressin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         In up to 20 percent of patients, chronic hypercalcemia leads to a defect in concentrating ability (arginine vasopressin resistance [AVP-R], previously called nephrogenic diabetes insipidus) and symptoms of polyuria and polydipsia. The mechanism is incompletely understood, but the downregulation of aquaporin-2 water channels and calcium deposition in the medulla with secondary tubulointerstitial injury and impaired generation of the interstitial osmotic gradient may play important roles. (See
         <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">
          "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"
         </a>
         .)
        </p>
        <p>
         In addition, some studies have demonstrated that activation of the normal calcium-sensing receptor by increases in the plasma calcium concentration can directly impair concentrating ability by affecting both the loop of Henle and the collecting tubules. (See
         <a class="medical medical_review" href="/z/d/html/838.html" rel="external">
          "Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">
          "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"
         </a>
         .)
        </p>
        <p>
         The combination of polyuria and diminished fluid intake secondary to gastrointestinal symptoms (nausea) can lead to dehydration, which exacerbates hypercalcemia and related symptoms.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Nephrolithiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         When hypercalcemia is due to primary hyperparathyroidism or sarcoidosis, it is often longstanding, and the resulting chronic hypercalciuria may cause nephrolithiasis. Increased calcitriol production may also play an important role in both diseases. The occurrence of nephrolithiasis in patients with these disorders is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis", section on 'Kidney stones'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">
          "Primary hyperparathyroidism: Clinical manifestations", section on 'Symptomatic primary hyperparathyroidism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Renal tubular acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic hypercalcemia infrequently causes type 1 (distal) renal tubular acidosis [
         <a href="#rid13">
          13
         </a>
         ]. The ensuing hypercalciuria and hypocitraturia can contribute to the development of nephrolithiasis. (See
         <a class="medical medical_review" href="/z/d/html/2369.html" rel="external">
          "Nephrolithiasis in renal tubular acidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Kidney insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of kidney insufficiency in individuals with hypercalcemia is related to the degree and duration of hypercalcemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild hypercalcemia is rarely associated with kidney insufficiency. In randomized trials of two to three years duration, there is little evidence that kidney function deteriorates in patients with mild chronic hypercalcemia due to hyperparathyroidism. (See
         <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">
          "Primary hyperparathyroidism: Management", section on 'Biochemical abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher elevations in the serum calcium concentration (serum calcium values of 12 to 15 mg/dL [3 to 3.75 mmol/L]) can lead to a reversible fall in glomerular filtration rate that is mediated by direct renal vasoconstriction and natriuresis-induced volume contraction [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longstanding hypercalcemia and hypercalciuria may lead to calcification, degeneration, and necrosis of the tubular cells and eventual tubular atrophy and interstitial fibrosis and calcification (nephrocalcinosis). Nephrocalcinosis, a condition observed in over one-half of hypercalcemic patients with kidney insufficiency, is the most common cause of chronic kidney disease in sarcoidosis. In comparison, nephrocalcinosis appears to be uncommon in patients with primary hyperparathyroidism [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7209.html" rel="external">
          "Nephrocalcinosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CARDIOVASCULAR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute hypercalcemia directly shortens the myocardial action potential, which is reflected in a shortened QT interval [
         <a href="#rid17">
          17
         </a>
         ]. Although there does not appear to be any clinically important effect of moderate hypercalcemia on cardiac conduction or the prevalence of supraventricular or ventricular arrhythmias [
         <a href="#rid18">
          18
         </a>
         ], arrhythmia has been described in patients with severe hypercalcemia [
         <a href="#rid19">
          19,20
         </a>
         ]. In addition, ST segment elevation mimicking myocardial infarction has been reported in such patients [
         <a href="#rid21">
          21-24
         </a>
         ].
        </p>
        <p>
         Longstanding hypercalcemia, as occurs in primary hyperparathyroidism, can lead to other cardiac abnormalities, including deposition of calcium in heart valves, coronary arteries, and myocardial fibers; hypertension; and cardiomyopathy. (See
         <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">
          "Primary hyperparathyroidism: Clinical manifestations", section on 'Cardiovascular'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          MUSCULOSKELETAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Profound muscle weakness was prominent in the original description of patients with hyperparathyroidism [
         <a href="#rid25">
          25
         </a>
         ]. This is not the case in the majority of such patients today (due in part to earlier diagnosis), but mild weakness may be apparent if looked for [
         <a href="#rid26">
          26
         </a>
         ]. In one prospective study, for example, nine patients were tested for neuromuscular performance before and four weeks after parathyroid surgery [
         <a href="#rid26">
          26
         </a>
         ]. All had an increase in muscle strength and improvement in fine motor movement, while there was no change in nonoperated patients. Weakness can be an important feature of other causes of hypercalcemia such as malignancy, but this can be a manifestation of the underlying illness rather than from hypercalcemia alone.
        </p>
        <p>
         Bone pain can occur in individuals with hypercalcemia due to malignancy or primary hyperparathyroidism. A reduction in cortical bone mass may occur in individuals with hyperparathyroidism. (See
         <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">
          "Primary hyperparathyroidism: Clinical manifestations", section on 'Skeletal'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          PHYSICAL FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are usually no specific physical findings of hypercalcemia other than those that might be related to an underlying disease, such as malignancy, and nonspecific findings related to dehydration. Band keratopathy, a reflection of subepithelial calcium phosphate deposits in the cornea, is a very rare finding [
         <a href="#rid27">
          27
         </a>
         ]. It extends as a horizontal band across the cornea in the area that is exposed between the eyelids; calcium salts probably precipitate in that site because of the higher local pH induced by the evaporation of CO
         <sub>
          2
         </sub>
         . It is usually detected by slit-lamp examination.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Hypercalcemia can affect a variety of organ systems  (
         <a class="graphic graphic_table graphicRef54647" href="/z/d/graphic/54647.html" rel="external">
          table 1
         </a>
         ). The symptoms of hypercalcemia depend upon both the degree of hypercalcemia and the rate of onset of the elevation in the serum calcium concentration. In addition, there is individual variation in the manifestation of symptoms. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with mildly elevated serum calcium concentrations (&lt;12 mg/dL [3 mmol/L]) are often asymptomatic, particularly if the elevation in serum calcium is chronic. Patients with moderately elevated calcium (12 to 14 mg/dL) may have symptoms of polyuria, polydipsia, anorexia, nausea, and constipation. In patients with severe hypercalcemia (calcium &gt;14 mg/dL [3.5 mmol/L]), there is often progression of these symptoms. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuropsychiatric manifestations
         </strong>
         – As the calcium concentration increases, symptoms can become more severe and include weakness, difficulty concentrating, confusion, stupor, and coma. (See
         <a class="local">
          'Neuropsychiatric'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal manifestations
         </strong>
         – Common gastrointestinal symptoms include constipation, anorexia, and nausea. (See
         <a class="local">
          'Gastrointestinal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney manifestations
         </strong>
         – The most common kidney manifestation of hypercalcemia is polyuria, due to a defect in concentrating ability, leading to dehydration. Chronic hypercalcemia associated with hypercalciuria can lead to nephrolithiasis or nephrocalcinosis. (See
         <a class="local">
          'Kidney'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular manifestations
         </strong>
         – Although uncommon, severe hypercalcemia can be associated with cardiac arrhythmia. Chronic hypercalcemia may lead to deposition of calcium in heart valves, coronary arteries, and myocardial fibers; hypertension; and cardiomyopathy. (See
         <a class="local">
          'Cardiovascular'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Shane E, Irani D. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6, Favus MJ (Ed), American Society for Bone and Mineral Research, Washington, DC 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker MD, Shane E. Hypercalcemia: A Review. JAMA 2022; 328:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inzucchi SE. Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. Postgrad Med 2004; 115:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohrvall U, Akerström G, Ljunghall S, et al. Surgery for sporadic primary hyperparathyroidism in the elderly. World J Surg 1994; 18:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner EC Jr, Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. South Med J 1981; 74:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnaille B, Oudar C, Pattou F, et al. Pancreatitis and primary hyperparathyroidism: forty cases. Aust N Z J Surg 1998; 68:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaur S. Sarcoidosis manifested as hypercalcemic pancreatitis. South Med J 2001; 94:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wynn D, Everett GD, Boothby RA. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol Oncol 2004; 95:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgain A, Acker O, Lambaudie E, et al. [Small cell carcinoma of the ovary of the hypercalcemic type revealed by a severe acute pancreatitis: about one case]. Gynecol Obstet Fertil 2005; 33:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mithöfer K, Fernández-del Castillo C, Frick TW, et al. Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. Gastroenterology 1995; 109:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward JB, Petersen OH, Jenkins SA, Sutton R. Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Lancet 1995; 346:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987; 102:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caruana RJ, Buckalew VM Jr. The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine (Baltimore) 1988; 67:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M, Ellis MA, Berl T. Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest 1983; 71:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lins LE. Reversible renal failure caused by hypercalcemia. A retrospective study. Acta Med Scand 1978; 203:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002; 17 Suppl 2:N87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed R, Hashiba K. Reliability of QT intervals as indicators of clinical hypercalcemia. Clin Cardiol 1988; 11:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenqvist M, Nordenström J, Andersson M, Edhag OK. Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism. Clin Endocrinol (Oxf) 1992; 37:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiewiet RM, Ponssen HH, Janssens EN, Fels PW. Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism. Neth J Med 2004; 62:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diercks DB, Shumaik GM, Harrigan RA, et al. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004; 27:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishi SP, Barbagelata NA, Atar S, et al. Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction. J Electrocardiol 2006; 39:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turhan S, Kilickap M, Kilinc S. ST segment elevation mimicking acute myocardial infarction in hypercalcaemia. Heart 2005; 91:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashizawa N, Arakawa S, Koide Y, et al. Hypercalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction. Intern Med 2003; 42:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manne JR. STriking Resemblance: Calcium-Alkali Syndrome. Am J Med 2016; 129:816.
          </a>
         </li>
         <li class="breakAll">
          Albright F, Reifenstein EC Jr. The Parathyroid Glands and Metabolic Bone Disease: Selected Cases, The Williams and Wilkins Company, Baltimore 1948.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery 1995; 117:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson KS, Alexander S, Chisholm IA. Band keratopathy in hypercalcemia of myeloma. Can Med Assoc J 1982; 126:1314.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 832 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Shane E, Irani D. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6, Favus MJ (Ed), American Society for Bone and Mineral Research, Washington, DC 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36282253" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hypercalcemia: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15095538" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Understanding hypercalcemia. Its metabolic basis, signs, and symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7725753" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Surgery for sporadic primary hyperparathyroidism in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7466439" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Primary hyperparathyroidism and the gastrointestinal tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9494002" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pancreatitis and primary hyperparathyroidism: forty cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11592759" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sarcoidosis manifested as hypercalcemic pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15581988" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15752664" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : [Small cell carcinoma of the ovary of the hypercalcemic type revealed by a severe acute pancreatitis: about one case].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7540999" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7475553" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2891201" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3127650" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6345587" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/645444" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Reversible renal failure caused by hypercalcemia. A retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12412783" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2899466" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Reliability of QT intervals as indicators of clinical hypercalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1424189" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15209475" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15261358" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Electrocardiographic manifestations: electrolyte abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16777515" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16020581" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : ST segment elevation mimicking acute myocardial infarction in hypercalcaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12729323" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hypercalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27154772" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : STriking Resemblance: Calcium-Alkali Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27154772" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : STriking Resemblance: Calcium-Alkali Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7809831" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7074461" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Band keratopathy in hypercalcemia of myeloma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
